INT118683

Context Info Confidence 0.44 First Reported 2004 Last Reported 2008 Negated 2 Speculated 0 Reported most in Body Documents 3 Total Number 4 Disease Relevance 2.92 Pain Relevance 1.82

nucleoplasm (MAPK3) mitochondrion (MAPK3) Golgi apparatus (MAPK3) protein complex assembly (MAPK3) protein complex (MAPK3) cytoplasm (MAPK3)

Anatomy Link Frequency colon 2 PFCX 2 MAPK3 (Homo sapiens)

Pain Link Frequency Relevance Heat Cannabinoid receptor 64 99.64 fluoxetine 7 98.82 agonist 8 98.80 antagonist 18 97.12 Osteoarthritis 178 94.20 rheumatoid arthritis 198 93.92 cINOD 10 70.64 Endocannabinoid 86 69.00 Hippocampus 1 65.60 Desipramine 1 61.64

Disease Link Frequency Relevance Heat Colon Cancer 6 99.70 Apoptosis 5 99.38 Urological Neuroanatomy 5 98.72 Frailty 180 94.20 Rheumatoid Arthritis 198 93.92 Cancer 9 71.60 INFLAMMATION 64 70.44 Disease 26 5.00 Arthritis 18 5.00 Pain 12 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Again in PFCX, FLX selectively increased the expression level of MAP kinases Erk1/2, without affecting their phosphorylation.

Neg (without) Regulation (affecting) of Phosphorylation (phosphorylation) of Erk1 in PFCX associated with urological neuroanatomy and fluoxetine

1) Confidence 0.44 Published 2004 Journal Neuropsychopharmacology Section Abstract Doc Link 15138445 Disease Relevance 0.40 Pain Relevance 0.61

Pharmacologic activation of PKG with YC-1 increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or beta-catenin protein expression.

Neg (without) Regulation (modulating) of Phosphorylation (phosphorylation) of ERK1 in colon associated with colon cancer and apoptosis

2) Confidence 0.44 Published 2006 Journal Mol. Cancer Ther. Section Abstract Doc Link 16546990 Disease Relevance 1.13 Pain Relevance 0.14

M) produced a time-dependent phosphorylation of ERK1, ERK2, and p38 MAPK, indicating an increase in ERK and p38 activity which peaked at 10 minutes after stimulation (Figure 6).

Regulation (dependent) of Phosphorylation (phosphorylation) of ERK1

3) Confidence 0.16 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2453762 Disease Relevance 1.04 Pain Relevance 0.65

To further investigate the role of the cannabinoid receptors in mediating the effects of HU210 on phosphorylation of ERK1, ERK2, and p38 MAPK, the potential ability of the CB1 and CB2 receptor antagonists SR141716A and SR144528 to block the effects of HU210 (0.1 ?

Regulation (effects) of Phosphorylation (phosphorylation) of ERK1 associated with cannabinoid receptor and antagonist

4) Confidence 0.10 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2453762 Disease Relevance 0.35 Pain Relevance 0.42

General Comments

This test has worked.